Mankind Pharma Q3 FY26 Earnings Call Transcript Released
Mankind Pharma's Q3 FY26 revenue rose 11.5% YoY to ₹3,567 crore, with adjusted EBITDA at 25.9%. 9M FY26 revenue increased 18.7% to ₹10,835 crore. Domestic revenue grew 11.1% in Q3. Chronic therapies like cardio and antidiabetic showed strong momentum. The transcript of the Q3 FY26 earnings call is now available.
The release of a conference call transcript is a standard disclosure practice for listed companies and typically does not have a significant immediate impact on the stock price unless it contains unexpected material information not previously disclosed.
The announcement is the release of a transcript for a conference call discussing financial results. While the results themselves may have positive aspects, the release of the transcript is a routine disclosure and does not introduce new material information that would significantly alter the company's outlook.
Mankind Pharma Limited has released the transcript of its Investor Conference Call for Q3 and 9M FY26, which was held on February 3, 2026.
The company reported an 11.5% year-on-year revenue increase to ₹3,567 crore for Q3 FY26, with an adjusted EBITDA margin of 25.9%. For the first 9 months of FY26, revenue grew by 18.7% year-on-year to ₹10,835 crore, with an adjusted EBITDA margin of 24.9%.
In Q3 FY26, domestic revenue grew by 11.1% year-on-year to ₹3,046 crore. The company's chronic therapies showed strong growth, with cardio up 16.7% and antidiabetic up 14.4%. Several brands crossed significant revenue milestones, with 13 brand families now exceeding ₹200 crore in sales.
The international business saw export revenues grow by 14% year-on-year to ₹521 crore in Q3 FY26. The company's Udaipur facility received EU GMP certification.
Financially, gross margins increased to 72.6% in Q3 FY26. Adjusted EBITDA margin was 25.9%, while reported EBITDA margin was 22.9% due to exceptional items. Finance costs decreased to ₹157 crore. Profit after tax grew by 9.5% year-on-year to ₹414 crore, with a PAT margin of 11.6%.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.